Doud­na’s new ven­ture; Aclaris CEO to step down; Tome’s $114M liv­er dis­or­der deal with Genevant

Plus, news about Ori­on, Stal­i­cla, Cyra­no Ther­a­peu­tics and In­stil Bio:

Jen­nifer Doud­na’s lat­est ven­ture: Her lab pub­lished a study Thurs­day in Na­ture Biotech­nol­o­gy de­tail­ing how an­ti­body frag­ments can be used to tar­get virus-like par­ti­cles with gene edit­ing ma­chin­ery to T cells. The fine print shows that Doud­na and the study’s first au­thor, Jen­ny Hamil­ton, co-found­ed Aza­lea Ther­a­peu­tics, a ge­net­ic med­i­cine de­liv­ery start­up. Aza­lea has raised $10 mil­lion, ac­cord­ing to a Forbes pro­file of found­ing sci­en­tist Con­nor Tsuchi­da. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER